Patient intake software firm Phreesia's Q3 revenue slightly beats estimates

Reuters
2025/12/09
Patient intake software firm Phreesia's Q3 revenue slightly beats estimates

Overview

  • Phreesia fiscal Q3 revenue slightly beats analyst expectations, growing 13% yr/yr

  • Net income for fiscal Q3 was $4.3 mln, compared to a loss last year

  • Company completed $160 mln acquisition of AccessOne, expected to boost future revenue

Outlook

  • Phreesia updates fiscal 2026 revenue outlook to $479 mln-$481 mln

  • Company raises fiscal 2026 adjusted EBITDA outlook to $99 mln-$101 mln

  • Phreesia introduces fiscal 2027 revenue outlook of $545 mln-$559 mln

Result Drivers

  • REVENUE PER CLIENT - Total revenue per healthcare services client increased by 6% year-over-year, contributing to overall revenue growth

  • CLIENT BASE EXPANSION - Average number of healthcare services clients grew by 7% year-over-year, supporting revenue increase

  • ACCESSONE ACQUISITION - Acquisition of AccessOne expected to enhance revenue and client offerings

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Slight Beat*

$120.33 mln

$120.05 mln (16 Analysts)

Q3 Net Income

$4.27 mln

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the software peer group is "buy"

  • Wall Street's median 12-month price target for Phreesia Inc is $34.00, about 67.6% above its December 5 closing price of $20.29

  • The stock recently traded at 87 times the next 12-month earnings vs. a P/E of 379 three months ago

Press Release: ID:nBw29NxcYa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10